Epitopea Adds Cancer Immunotherapy Veteran Lisa Butterfield to Scientific Advisory Board
Event summary
- Lisa Butterfield, a leading authority in cancer immunotherapy, joins Epitopea's Scientific Advisory Board on April 13, 2026.
- Butterfield brings expertise in cancer vaccines, immune profiling, and biomarker development, with over 200 peer-reviewed publications.
- Her appointment supports Epitopea's advancement of RNA-based immunotherapies, including lead candidate CryptiVax™-1001 for ovarian cancer.
- Butterfield previously held roles at Merck, the Parker Institute for Cancer Immunotherapy, and academic leadership positions at the University of Pittsburgh.
The big picture
Epitopea's appointment of Lisa Butterfield underscores the growing emphasis on RNA-based immunotherapies for solid tumors, a field increasingly dominated by off-the-shelf solutions. Butterfield's dual expertise in academia and industry positions Epitopea to bridge translational gaps, a critical advantage as the company navigates the competitive landscape of cancer immunotherapy. Her leadership roles in key organizations like SITC and the FDA further bolster Epitopea's regulatory and scientific credibility.
What we're watching
- Clinical Progression
- How quickly Epitopea advances CryptiVax™-1001 into the clinic with Butterfield's strategic guidance.
- Pipeline Expansion
- Whether Butterfield's expertise accelerates the development of Epitopea's broader pipeline of RNA-based immunotherapies.
- Industry Collaboration
- The pace at which Epitopea leverages Butterfield's extensive network to forge new partnerships in cancer immunotherapy.
Our editorial coverage:
Related topics